FLNA抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-3: PC3 cells, NIH/3T3 cells, HUVEB cells, Primary antibody: P08338(FLNA Antibody) at dilution 1/1100, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08338(FLNA Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08338(FLNA Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of FLNA Antibody**

Filamin A (FLNA), encoded by the *FLNA* gene, is a cytoskeletal protein crucial for cell structure, motility, and signaling. It crosslinks actin filaments into dynamic networks, facilitating cell adhesion, migration, and mechanotransduction. FLNA also interacts with integrins, ion channels, and signaling molecules (e.g., β-catenin), influencing pathways like Wnt and NF-κB.

Mutations in *FLNA* are linked to diverse disorders, including X-linked periventricular nodular heterotopia (PVNH, causing neuronal migration defects), frontometaphyseal dysplasia, and cardiovascular abnormalities. FLNA dysfunction may also contribute to cancer metastasis and platelet disorders.

FLNA antibodies are essential tools in research and diagnostics. They detect FLNA expression, localization, and post-translational modifications via techniques like Western blot, immunohistochemistry, and immunofluorescence. These antibodies help study FLNA's roles in cellular processes and disease mechanisms. In clinical contexts, they aid in diagnosing FLNA-related disorders by identifying protein abnormalities in patient tissues. Commercial FLNA antibodies vary in specificity (monoclonal vs. polyclonal) and applications, requiring validation for experimental accuracy. Ongoing research explores FLNA's potential as a therapeutic target or biomarker in cancers and genetic syndromes.